Profiling protein markers associated with the sensitivity to concurrent chemoradiotherapy in human cervical carcinoma

Journal of Proteome Research

Volumn 8, Issue 8, 2009, Pages 3969-3976

  Zhu, Hong ^a   Pei, Hai Ping ^a   Zeng, Shan ^a   Chen, Jia ^a   Shen, Liang Fang ^a   Zhong, Mei Zuo ^a   Yao, Ruo Jing ^a   Shen, Hong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cervical carcinoma; Concurrent chemoradiotherapy; Protein markers; Sensitivity

Indexed keywords

CALGRANULIN B; CISPLATIN; GALECTIN 7; HEAT SHOCK PROTEIN 70; NUCLEAR MATRIX PROTEIN; PACLITAXEL; PROTEIN NMP 238; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHEMOSENSITIVITY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY; TWO DIMENSIONAL ELECTROPHORESIS; UTERINE CERVIX CARCINOMA; WESTERN BLOTTING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; MIDDLE AGED; PEPTIDE MAPPING; PREDICTIVE VALUE OF TESTS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 68549130927     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr900287a     Document Type: Article

References (39)

1. Ryu, H. S. Concurrent chemoradiotherapy in cervical cancer (a new paradigm in cervical cancer treatment. Yonsei Med. J. 2002, 43 (6), 749-53.
2. Dreyer, G.; Snyman, L. C.; Mouton, A.; Lindeque, B. G. Management of recurrent cervical cancer. Best Pract. Res. Clin., Obstet. Gynaecol. 2005, 19 (4), 631-44.
3. Datta, N. R.; Agrawal, S. Does the evidence support the use of concurrent chemoradiotherapy as a standard in the management of locally advanced cancer of the cervix, especially in developing countries? Clin. Oncol. 2006, 18 (4), 306-12.
4. Morris, M.; Eifel, P. J.; Lu, J.; Grigsby, P. W.; Levenback, C.; Stevens, R. E. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N. Engl. J. Med. 1999, 340 (15), 1137-43.
5. Peters, W. A., III; Liu, P. Y.; Barrett, R. J., II; Stock, R. J.; Monk, B. J.; Berek, J. S. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J. Clin. Oncol. 2000, 18 (8), 1606-13.
6. Rose, P. G.; Bundy, B. N.; Watkins, E. B.; Thigpen, J. T.; Deppe, G.; Maiman, M. A. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N. Engl. J. Med. 1999, 340 (15), 1144-53.
7. Whitney, C. W.; Sause, W.; Bundy, B. N.; Malfetano, J. H.; Hannigan, E. V.; Fowler, W. C., Jr. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J. Clin. Oncol. 1999, 17 (5), 1339-48.
8. McArdle, O.; Kigula-Mugambe, J. B. Contraindications to cisplatin based chemoradiotherapy in the treatment of cervical cancer in Sub-Saharan Africa. Radiother. Oncol. 2007, 83 (1), 94-6.
9. Classe, J. M.; Rauch, P.; Rodier, J. F.; Morice, P.; Stoeckle, E.; Lasry, S. Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervical cancer: morbidity and outcome: results of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer). Gynecol. Oncol. 2006, 102 (3), 523-9.
10. King, M.; McConkey, C.; Latief, T. N.; Hartley, A.; Fernando, I. Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-effects. Clin. Oncol. 2006, 18 (1), 38-45.
11. Chen, S. W.; Liang, J. A.; Hung, Y. C.; Yeh, L. S.; Chang, W. C.; Lin, W. C. Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications. Int. J. Radiat. Oncol. Biol. Phys. 2006, 66 (5), 1370-7.
12. Torres, M. A.; Jhingran, A.; Thames, H. D., Jr.; Levenback, C. F.; Bodurka, D. C.; Ramondetta, L. M. Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment. Int. J. Radiat. Oncol. Biol. Phys. 2008, 70 (1), 118-25.
13. Choi, Y. P.; Kang, S.; Hong, S.; Xie, X.; Cho, N. H. Proteomic analysis of progressive factors in uterine cervical cancer. Proteomics 2005, 5 (6), 1481-93.
14. Creasman, W. T. New gynecologic cancer staging. Gynecol. Oncol. 1995, 58 (2), 157-8.
15. Chan, W. K.; Aroney, R. S.; Levi, J. A.; Tattersall, M. H.; Fox, R. M.; Woods, R. L. Four-drug combination chemotherapy for advanced cervical carcinoma. Cancer 1982, 49 (12), 2437-40.
16. Pei, H.; Zhu, H.; Zeng, S.; Li, Y.; Yang, H.; Shen, L. Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer. J. Proteome Res. 2007, 6 (7), 2495-501.
17. Miglietta, L.; Franzone, P.; Centurioni, M. G.; Boni, L.; Tacchini, L.; Cosso, M. A phase II trial with cisplatin-paclitaxel cytotoxic treatment and concurrent external and endocavitary radiation therapy in locally advanced or recurrent cervical cancer. Oncology 2006, 70 (1), 19-24.
18. Shen, H.; Fan, J.; Burczynski, F.; Minuk, G. Y.; Cattini, P.; Gong, Y. Increased Smad1 expression and transcriptional activity enhances trans-differentiation of hepatic stellate cells. J. Cell Physiol. 2007, 212 (3), 764-70.
19. Shen, H.; Fan, Y.; Yang, X.; Burczynski, F. J.; Li, P.; Gong, Y. Increased expression of cystic fibrosis transmembrane conductance regulator in rat liver after common bile duct ligation. J. Cell Physiol. 2005, 203 (3), 599-603.
20. Ilyas, M.; Hao, X. P.; Wilkinson, K.; Tomlinson, I. P.; Abbasi, A. M.; Forbes, A.; et al. Loss of Bcl-2 expression correlates with tumour recurrence in colorectal cancer. Gut 1998, 43 (3), 383-7.
21. Lee, K. H.; Yim, E. K.; Kim, C. J.; Namkoong, S. E.; Um, S. J.; Park, J. S. Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol. Oncol. 2005, 98 (1), 45-53.
22. Castagna, A.; Antonioli, P.; Astner, H.; Hamdan, M.; Righetti, S. C.; Perego, P.; et al. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 2004, 4 (10), 3246-67.
23. Harima, Y.; Harima, K.; Shikata, N.; Oka, A.; Ohnishi, T.; Tanaka, Y. Bax and Bcl-2 expressions predict response to radiotherapy in human cervical cancer. J. Cancer Res. Clin. Oncol. 1998, 124 (9), 503-10.
24. West, C. M.; McKay, M. J.; Holscher, T.; Baumann, M.; Stratford, I. J.; Bristow, R. G.; et al. Molecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62 (5), 1264-73.
25. Melle, C.; Ernst, G.; Schimmel, B.; Bleul, A.; Koscielny, S.; Wiesner, A.; et al. A technical triade for proteomic identification and characterization of cancer biomarkers. Cancer Res. 2004, 64 (12), 4099-104.
26. Arai, K.; Teratani, T.; Kuruto-Niwa, R.; Yamada, T.; Nozawa, R. S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation. Eur. J. Cancer 2004, 40 (8), 1179-87.
27. Ghavami, S.; Kerkhoff, C.; Los, M.; Hashemi, M.; Sorg, C.; Karami-Tehrani, F. Mechanism of apoptosis induced by S100A8/A9 in colon cancer cell lines: the role of ROS and the effect of metal ions. J. Leukocyte Biol. 2004, 76 (1), 169-75.
28. Kuwabara, I.; Kuwabara, Y.; Yang, R. Y.; Schuler, M.; Green, D. R.; Zuraw, B. L.; et al. Galectin-7 (PIG1) exhibits pro-apoptotic function through JNK activation and mitochondrial cytochrome c release. J. Biol. Chem. 2002, 277 (5), 3487-97.
29. Brondani Da Rocha, A.; Regner, A.; Grivicich, I.; Pretto Schunemann, D.; Diel, C.; Kovaleski, G.; et al. Radioresistance is associated to increased Hsp70 content in human glioblastoma cell lines. Int. J. Oncol. 2004, 25 (3), 777-85.
30. Park, S. H.; Lee, S. J.; Chung, H. Y.; Kim, T. H.; Cho, C. K.; Yoo, S. Y.; et al. Inducible heat-shock protein 70 is involved in the radioadaptive response. Radiat. Res. 2000, 153 (3), 318-26.
31. Demidenko, Z. N.; Vivo, C.; Halicka, H. D.; Li, C. J.; Bhalla, K.; Broude, E. V.; et al. Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor-and cycle-arrest-mediated cytoprotection. Cell Death Differ. 2006, 13 (9), 1434-41.
32. Ray, S.; Lu, Y.; Kaufmann, S. H.; Gustafson, W. C.; Karp, J. E.; Boldogh, I.; et al. Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis. J. Biol. Chem. 2004, 279 (34), 35604-15.
33. Ahn, E. Y.; Pan, G.; Oh, J. H.; Tytler, E. M.; McDonald, J. M. The combination of calmodulin antagonists and interferon-gamma induces apoptosis through caspase-dependent and -independent pathways in cholangiocarcinoma cells. Am. J. Pathol. 2003, 163 (5), 2053-63.
34. Durnez, A.; Verslype, C.; Nevens, F.; Fevery, J.; Aerts, R.; Pirenne, J.; et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006, 49 (2), 138-51.
35. Yuan, C. C.; Huang, H. C.; Tsai, L. C.; Ng, H. T.; Huang, T. S. Cytokeratin-19 associated with apoptosis and chemosensitivity in human cervical cancer cells. Apoptosis 1997, 2 (1), 101-5.
36. Lee, Y. J.; Sheu, T. J.; Keng, P. C. Enhancement of radiosensitivity in H1299 cancer cells by actin-associated protein cofilin. Biochem. Biophys. Res. Commun. 2005, 335 (2), 286-91.
37. Paley, E. L. Tryptamine-mediated stabilization of tryptophanyl-tRNA synthetase in human cervical carcinoma cell line. Cancer Lett. 1999, 137 (1), 1-7.
38. Choi, Y. S.; Yi, C. M.; Sin, J. I.; Ye, G. W.; Shin, I. H.; Lee, T. S. Impact of hemoglobin on survival of cervical carcinoma patients treated with concurrent chemoradiotherapy is dependent on lymph node metastasis findings by magnetic resonance imaging. Int. J. Gynecol. Cancer 2006, 16 (5), 1846-54.
39. Saussez, S.; Cucu, D. R.; Decaestecker, C.; Chevalier, D.; Kaltner, H.; Andre, S.; et al. Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Ann. Surg. Oncol. 2006, 13 (7), 999-1009.